Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia

Merck’s LIPFENDRA (once-daily oral PCSK9 inhibitor) received U.S. FDA approval as the first and only once-daily oral therapy to reduce LDL-C in adults with hypercholesterolemia. The approval is a positive regulatory milestone that could expand Merck’s competitive position in lipid-lowering treatment and support future revenue growth, though no commercial uptake metrics were provided.

Analysis

Merck’s LIPFENDRA (once-daily oral PCSK9 inhibitor) received U.S. FDA approval as the first and only once-daily oral therapy to reduce LDL-C in adults with hypercholesterolemia. The approval is a positive regulatory milestone that could expand Merck’s competitive position in lipid-lowering treatment and support future revenue growth, though no commercial uptake metrics were provided.